FOXI1

Across TCGA pan-cancer cohorts, FOXI1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FOXI1 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher FOXI1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FOXI1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM, CESC, and HNSC are the cancer types where FOXI1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.897	0.547	<.001	34	view →
CESC	OS	Median	All	0.198	0.800	<.001	24	view →
HNSC	OS	Median	All	0.257	0.713	.004	19	view →
LGG	DFS	Median	All	0.233	0.739	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FOXI1–SKCM (DFS)

Open the SKCM breakdown →